At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 16, 2026 at 09:47 ET
Ameriprise Financial disclosed an 8.6% passive beneficial ownership stake in Yarrow Bioscience as of September 30, 2026, primarily through its Columbia Small Cap Growth Fund (6.3%). This adds to a series of recent 13G filings by other institutions following Yarrow's September 2026 equity offering, with no activist intent indicated.
- Ameriprise Financial, Inc. disclosed a 8.6% beneficial ownership stake in Yarrow Bioscience as of September 30, 2026.
- The stake comprises 739,538 shares of common stock, with 539,115 shares held by Columbia Small Cap Growth Fund (6.3%).
- The filing is a passive Schedule 13G under Rule 13d-1(b), certifying no intent to influence control.
- This follows recent 13G filings by Bellevue Group (10.6%), Spruce Street Capital (6.4%), and others after Yarrow's $172.5M September 2026 equity offering.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access